Wednesday, December 05, 2018 Dr. Kim Chi, Medical Oncologist, and Medical Director at BC Cancer who is leading the IND.234 trial At a press conference last week CCTG announced a new clinical trial, opening across Canada. IND.234 is considered a major advancement in precision medicine for prostate cancer and the first of its kind in the world. The IND.234 clinical trial, uses liquid biopsy technology to screen for genomic markers in prostate cancer patients. Read more.
